On November 10, 2026 Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") reported that on November 4, 2026, the Company and its wholly owned subsidiary, GPCR Therapeutics USA Inc. ("GPCR USA"), entered into an Intellectual Property, Asset and License Assignment Agreement (the "Agreement") with GPCRT Inc. ("GPCRT"), a company organized under the laws of the Republic of Korea, under which GPCRT has agreed to acquire the Company’s GPC-100 (burixafor) program assets for an aggregate cash purchase price of KRW 6.5 billion (approximately US$4.8 million).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The assets to be sold consist of the Company’s rights under its License and Collaboration Agreement with GPCR Therapeutics, Inc. dated January 19, 2025, together with the related contracts, intellectual property, clinical and regulatory data, materials and equipment of the Company and GPCR USA used in the GPC-100 program. GPC-100 is being evaluated in combination with propranolol for stem cell mobilization in patients with multiple myeloma, and GPCR USA completed its Phase 2 clinical trial of GPC-100 in January 2026. GPCR USA will remain a wholly owned subsidiary of Exicure following the closing.

Of the purchase price, KRW 500 million has previously been paid by GPCRT and will be credited against the purchase price, KRW 2.0 billion is payable on or before November 16, 2026 and the remaining KRW 4.0 billion is payable at the closing, in each case subject to any other payment date agreed by the parties in writing. From and after the closing, GPCRT will assume the obligations under the License and Collaboration Agreement, including future milestone and royalty payments, and under the assigned program contracts, and GPCRT will bear the costs of the GPC-100 program incurred on or after September 1, 2026, as provided in the Agreement. Exicure and GPCR USA will retain all other liabilities, including GPC-100 program liabilities incurred before September 1, 2026.

The closing is subject to customary closing conditions, including required approvals and third-party consents, a waiver and release from GPCR Therapeutics, Inc. and any approval of the Company’s stockholders that may be required. There can be no assurance that the transaction will be completed on the anticipated timetable or at all.

The sale of the GPC-100 program assets is part of the Company’s ongoing evaluation of strategic alternatives intended to maximize stockholder value and is expected to strengthen the Company’s financial position.

Additional information regarding the Agreement is included in the Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission (the "SEC").

(Press release, Exicure, NOV 10, 2026, View Source [SID1234674557])